No added benefit from nebulized amiloride in patients with cystic fibrosis

In cystic fibrosis (CF) airway epithelial sodium absorption is increased 2-3 fold. Since sodium absorption is inhibited by the sodium channel blocker amiloride, our aim was to assess its therapeutic benefit in cystic fibrosis. A randomized, double-blind, placebo-controlled, cross-over trial of nebulized amiloride was performed in 23 patients with cystic fibrosis. Amiloride or placebo was administered four times daily for two six month periods. Existing treatment was continued, and any infective exacerbations treated in the usual way. Fourteen patients completed the study. No significant changes occurred in forced expiratory volume in one second, forced vital capacity, oxygen saturation, body weight, sputum volume, culture and rheology, serum urea, and electrolytes, white cell count and erythrocyte sedimentation rate during either treatment period. The frequency of infective exacerbations was also not different in either treatment period. We were thus unable to confirm the benefit shown in the only other clinical trial of nebulized amiloride in cystic fibrosis and conclude that, in the presence of established treatment for cystic fibrosis lung disease, nebulized amiloride offers no additional clinical benefit.

This article has been cited by other articles:

				K. R. Flaherty Clinical Year in Review IV: Pediatric Pulmonary and Critical Care, Cystic Fibrosis, Asthma, and Pleural Disease Proceedings of the ATS, September 15, 2009; 6(6): 506 - 511. [Full Text] [PDF]

				K. Coote, H. C. Atherton-Watson, R. Sugar, A. Young, A. MacKenzie-Beevor, M. Gosling, G. Bhalay, G. Bloomfield, A. Dunstan, R. J. Bridges, et al. Camostat Attenuates Airway Epithelial Sodium Channel Function in Vivo through the Inhibition of a Channel-Activating Protease J. Pharmacol. Exp. Ther., May 1, 2009; 329(2): 764 - 774. [Abstract] [Full Text] [PDF]

				Z. Zhou, D. Treis, S. C. Schubert, M. Harm, J. Schatterny, S. Hirtz, J. Duerr, R. C. Boucher, and M. A. Mall Preventive but Not Late Amiloride Therapy Reduces Morbidity and Mortality of Lung Disease in {beta}ENaC-overexpressing Mice Am. J. Respir. Crit. Care Med., December 15, 2008; 178(12): 1245 - 1256. [Abstract] [Full Text] [PDF]

				A. J. Hirsh, J. Zhang, A. Zamurs, J. Fleegle, W. R. Thelin, R. A. Caldwell, J. R. Sabater, W. M. Abraham, M. Donowitz, B. Cha, et al. Pharmacological Properties of N-(3,5-Diamino-6-chloropyrazine-2-carbonyl)-N'-4-[4-(2,3-dihydroxypropoxy)phenyl]butyl-guanidine Methanesulfonate (552-02), a Novel Epithelial Sodium Channel Blocker with Potential Clinical Efficacy for Cystic Fibrosis Lung Disease J. Pharmacol. Exp. Ther., April 1, 2008; 325(1): 77 - 88. [Abstract] [Full Text] [PDF]

				M. D. Carattino, C. J. Passero, C. A. Steren, A. B. Maarouf, J. M. Pilewski, M. M. Myerburg, R. P. Hughey, and T. R. Kleyman Defining an inhibitory domain in the {alpha}-subunit of the epithelial sodium channel Am J Physiol Renal Physiol, January 1, 2008; 294(1): F47 - F52. [Abstract] [Full Text] [PDF]

				S. H. Donaldson and R. C. Boucher Sodium Channels and Cystic Fibrosis Chest, November 1, 2007; 132(5): 1631 - 1636. [Abstract] [Full Text] [PDF]

				P. G. Middleton, T. J. Kidd, and B. Williams Combination aerosol therapy to treat Burkholderia cepacia complex Eur. Respir. J., August 1, 2005; 26(2): 305 - 308. [Abstract] [Full Text] [PDF]

				A. J. Hirsh, J. R. Sabater, A. Zamurs, R. T. Smith, A. M. Paradiso, S. Hopkins, W. M. Abraham, and R. C. Boucher Evaluation of Second Generation Amiloride Analogs as Therapy for Cystic Fibrosis Lung Disease J. Pharmacol. Exp. Ther., December 1, 2004; 311(3): 929 - 938. [Abstract] [Full Text] [PDF]

				R. J. Bridges, B. B. Newton, J. M. Pilewski, D. C. Devor, C. T. Poll, and R. L. Hall Na+ transport in normal and CF human bronchial epithelial cells is inhibited by BAY 39-9437 Am J Physiol Lung Cell Mol Physiol, July 1, 2001; 281(1): L16 - L23. [Abstract] [Full Text] [PDF]

				H.C. Rodgers and A.J. Knox Pharmacological treatment of the biochemical defect in cystic fibrosis airways Eur. Respir. J., June 1, 2001; 17(6): 1314 - 1321. [Abstract] [Full Text] [PDF]

				D. C. Devor, R. J. Bridges, and J. M. Pilewski Pharmacological modulation of ion transport across wild-type and Delta F508 CFTR-expressing human bronchial epithelia Am J Physiol Cell Physiol, August 1, 2000; 279(2): C461 - C479. [Abstract] [Full Text] [PDF]

				T. HOFMANN, M. J. STUTTS, A. ZIERSCH, C. RUCKES, W. M. WEBER, M. R. KNOWLES, H. LINDEMANN, and R. C. BOUCHER Effects of Topically Delivered Benzamil and Amiloride on Nasal Potential Difference in Cystic Fibrosis Am. J. Respir. Crit. Care Med., June 1, 1998; 157(6): 1844 - 1849. [Abstract] [Full Text] [PDF]

				R. C. Stern The Diagnosis of Cystic Fibrosis N. Engl. J. Med., February 13, 1997; 336(7): 487 - 491. [Full Text] [PDF]